Fusion Antibodies (FAB) RNS Announcements

Add to Alert list
Date Time Source Announcement
21 Sep 2018 11:24 AM
RNS
Result of AGM
28 Aug 2018 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
16 Aug 2018 07:00 AM
RNS
Final Results
13 Aug 2018 07:00 AM
RNS
Trading Update
20 Jun 2018 01:06 PM
RNS
Ongoing discussions with MAB Discovery
24 May 2018 07:00 AM
RNS
Receipt of additional grants from Invest NI
09 May 2018 03:40 PM
RNS
Holding(s) in Company
23 Apr 2018 10:09 AM
RNS
Investor presentation
05 Mar 2018 07:00 AM
RNS
Trading Statement
01 Mar 2018 07:00 AM
RNS
Receipt of grants from Invest Northern Ireland
16 Jan 2018 10:06 AM
RNS
Director dealing
21 Dec 2017 09:35 AM
RNS
Holding(s) in Company
21 Dec 2017 09:33 AM
RNS
Holding(s) in Company
19 Dec 2017 07:00 AM
RNS
Holding(s) in Company
19 Dec 2017 07:00 AM
RNS
Holding(s) in Company
18 Dec 2017 08:00 AM
RNS
Admission to AIM and first day of dealings

Fusion Antibodies is a biotechnology company that specializes in antibody development services for the healthcare industry. The company was founded in 2001 as a spin-out from Queen's University Belfast and is headquartered in Belfast, Northern Ireland. Fusion Antibodies offers antibody discovery, engineering, supply, and cell line development. It has developed proprietary technology platforms such as CDRx® for antibody humanization, RAMP® for affinity maturation, and ADD™ for developability optimization.

FAB share price launched at 165p in 2017.

UK 100

Latest directors dealings